Fluocinolone acetonide - Eclipse Life Sciences
Alternative Names: EC-104Latest Information Update: 03 Sep 2024
At a glance
- Originator Eclipse Life Sciences
- Class Anti-inflammatories; Antipruritics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules; Vasoconstrictors
- Mechanism of Action Glucocorticoid receptor agonists; Nitric oxide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Diabetic macular oedema
Most Recent Events
- 12 Aug 2024 Phase-I/II clinical trials in Diabetic macular oedema in USA (Intravitreous) (NCT06536491)
- 08 Aug 2024 Eclipse Life Sciences has patent protection for intravitreal multiphasic colloidal suspension-drug delivery system (Eclipse Life Sciences pipeline, August 2024)
- 08 Aug 2024 Preclinical trials in Diabetic macular oedema in USA (Intravitreous) prior to August 2024 (Eclipse Life Sciences pipeline, August 2024)